Work

68 EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – potential treatment for CSU and beyond

Year: 2023

Type: article

Source: Journal of Investigative Dermatology

DOI: 10.1016/j.jid.2023.09.076

Authors: J. Harden, J. Folkerts, S.-Y. Tam, S. Frischbutter, M. Babina, H.E. Hofland, J.P. Patel, M. Maurer, S.J. Galli

Institutions: Stanford University, Humboldt-Universität zu Berlin, Fraunhofer Institute for Translational Medicine and Pharmacology, Charité - Universitätsmedizin Berlin

Language: English

Topic: Mast cells and histamine

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388415574

FWCI: 0.175

Cites:

Cited by: 2

Related to: 10